Entopsis company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Unattributed | Alive

Total Raised


Last Raised

$1.04M | 1 yr ago

About Entopsis

Entopsis is a privately held company developing novel biomedical products for research and clinical use, predominantly in the areas of oncology, autoimmune disorders, metabolic disorders and developing world malignancies. The company has established various strategic industry and academic research collaborations geared towards advancing company goals.

Entopsis Headquarter Location

7600 NW 69th Ave

Miami, Florida, 33166,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Entopsis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Entopsis is included in 4 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Entopsis Patents

Entopsis has filed 2 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Analytical chemistry
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics



Molecular biology, Blood tests, Transfusion medicine, Blood, Biotechnology


Application Date


Grant Date


Related Topics

Molecular biology, Blood tests, Transfusion medicine, Blood, Biotechnology



Latest Entopsis News

Entopsis Exploring Strategic Alternatives for its OpsisDx™ Platform

Oct 7, 2021

News provided by Share this article Share this article MEDLEY, Fla., Oct. 7, 2021 /PRNewswire/ -- Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, today announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of early-stage cancers. Its IP-protected platform detects urine chemical signatures via a proprietary array, achieving clinically significant results through its proprietary machine learning algorithms. Validation studies on OpsisDxTM have initially focused on detecting early-stage cancers, and the platform has now expanded to detecting multiple other diseases in a highly scalable fashion. "Now is the time to launch OpsisDxTM. There's greater acceptance of multi-disease testing platforms from a scientific, regulatory and business perspective; the industry as a whole has crossed the tipping point," said Obdulio Piloto, CEO of Entopsis Inc. "We are seeking an established partner who shares our vision of empowering people with actionable, low costs and accurate healthcare information with an eye towards the long-term interests of Entopsis. "  Please direct all inquiries to Lou Grecco ( [email protected] ) and Steven Quinn ( [email protected] ) at Berkery Noyes & Co. SOURCE Berkery, Noyes & Co.

Entopsis Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Entopsis Rank

  • When was Entopsis founded?

    Entopsis was founded in 2011.

  • Where is Entopsis's headquarters?

    Entopsis's headquarters is located at 7600 NW 69th Ave, Miami.

  • What is Entopsis's latest funding round?

    Entopsis's latest funding round is Unattributed.

  • How much did Entopsis raise?

    Entopsis raised a total of $2.77M.

  • Who are the investors of Entopsis?

    Investors of Entopsis include Krillion Ventures and Breakout Labs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.